POET Technologies: When a $830 Million Cash Pile Meets a 68% Rout

Despite $830M in funding and a 2027 production target, POET shares have lost 68% from their high, hit by a Marvell order cancellation and PFIC lawsuits.

The numbers tell two starkly different stories about POET Technologies, and neither one is easy to reconcile with the other. On one side sits a company that has raised $830 million in equity financing, secured a five-year supply agreement potentially worth over $500 million with Lumilens, and laid out a production roadmap targeting one million optical engine units per month by the end of 2027. On the other side sits a stock that has shed nearly 68 percent from its May 15 high of €18.84, now trading at €6.04 — below its own 200-day moving average of €6.84.

That gap between ambition and market reception is the defining feature of POET today. The shares have lost roughly 30 percent in the past 30 days alone, with the slide accelerating after a single-day collapse of 45 to 47 percent on April 27. That crash was triggered by the cancellation of all orders from Marvell's Celestial AI division, following reports that a senior POET manager had breached a confidentiality agreement in a public interview. The event laid bare how concentrated the company's customer base remains — one client's withdrawal erased nearly half the company's market value in a single session.

Legal Overhang Compounds the Selloff

The Marvell fallout was not an isolated incident. Multiple law firms have filed lawsuits alleging that POET misrepresented its U.S. tax status, specifically regarding its potential classification as a Passive Foreign Investment Company (PFIC). The class-action window runs from April 1 to April 27, 2026. The litigation remains unresolved, and the uncertainty has kept a lid on any recovery attempts. Even as late as July, the stock dropped another 6.84 percent in a single day on weak demand signals, underscoring how fragile investor sentiment has become.

The relative strength index now sits at 37.2, edging toward oversold territory but without any confirmed trend reversal. The annualized 30-day volatility stands above 90 percent, meaning the shares can swing by a third of their value in either direction on little more than a mood shift. That is not noise — it is the pattern for a stock whose fundamentals have not changed but whose market perception has soured dramatically.

The Production Roadmap Remains Intact

None of this has deterred management from pressing ahead. The plan to begin production of optical engines in the second half of 2026 remains on track, with capacity targets of one million units per month by end-2027. Capital expenditure of roughly $50 million in production equipment is budgeted, backed by the $830 million equity raise completed last year. An additional $661 million could flow in through warrants.

At the annual general meeting, shareholders voted overwhelmingly to re-elect the entire board and reappoint Davidson & Company LLP as auditors. Management also highlighted more than ten active customer discussions with a combined annual revenue potential exceeding $100 million. The Lumilens agreement, which starts with an initial $50 million order and could scale to over $500 million over five years, is the most tangible sign of diversification away from the Marvell relationship.

The Blazar hybrid laser program, meanwhile, is scheduled for broad deployment in 2028. On paper, the story has not changed.

A Market That Demands Proof, Not Promises

The disconnect is that none of this operational optimism has arrested the stock's decline. The market is pricing in execution risk, customer concentration risk, and legal risk simultaneously — and it is assigning a heavy discount to future revenues that have yet to materialize. At a market capitalization of roughly €417 million, POET is valued at a fraction of what a successful scale-up to one million monthly units would justify. But the path to that scale requires flawless execution across production, customer conversion, and capital discipline, with almost no room for delay.

The twelve-month return still shows a gain of 22.52 percent, so long-term holders who entered a year ago are not underwater. But the journey has been brutal: a stock that can lose a third of its value in a month, recover, then lose it again, tests the patience of even the most committed believers. The RSI of 37.2 suggests a technical bounce is possible, but the legal overhang and the absence of a clear catalyst make any sustained recovery uncertain.

The Burden of Proof Has Shifted

POET now finds itself in a position familiar to speculative growth stocks: the distance to the high is enormous, and the distance to the low is even larger. The company has the balance sheet to weather the storm — the $830 million war chest is real, and the Lumilens deal provides a credible path away from single-client dependency. But the lawsuits remain unresolved, the Marvell relationship lies in ruins, and the market is demanding evidence that the production ramp will actually begin in the second half of 2026 as promised.

Until that evidence arrives, the stock will remain a prisoner of sentiment, swinging violently on every piece of news — whether it is a court date or a production update. The management team carries the burden of proof now. The roadmap alone will not be enough to rebuild the trust that was lost on April 27.